Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer ...

The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Abrupt end of Pfizer's hemophilia A gene therapy deal with Sangamo is the latest in a line of flip-flops between the big drug ...

Key Takeaways Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement ...

9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...